Epidemiology guidance
Executive Summary
FDA is considering developing a guidance on the use of epidemiological data in order to facilitate post-marketing surveillance. The document would advise industry on the analysis of large safety databases. The expansion of funding for post-market drug surveillance activities is under discussion as part of the fourth renewal of the Prescription Drug User Fee Act next year (1"The Pink Sheet" Nov. 21, 2005, p. 3)...
You may also be interested in...
PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions
FDA is emphasizing the difficulties of industry requested meetings in its early public discussion of the 2007 Prescription Drug User Fee Act reauthorization
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: